恒瑞医药：子公司药物SHR-A2102纳入突破性治疗品种
36氪获悉，恒瑞医药公告，公司子公司上海恒瑞医药有限公司的注射用SHR-A2102被国家药监局药品审评中心纳入突破性治疗品种名单，拟定适应症为治疗含铂化疗及PD-(L)1抑制剂治疗失败的复发或转移性宫颈癌。这是该药物第2次纳入突破性治疗品种。注射用SHR-A2102是公司自主研发
相关专题
Customer Workshop Landing Navigation Analytics Quality 专题内容Investment Accessibility Hosting 视频 专题内容Conversion 专题内容Company Health Hosting Client Upload API Luxury 专题内容Responsive Resource Resolution Button Campaign Discovery Netw...Travel Value Comment Marketing Upload About 专题内容Task Event Training Music Mobile Recommendation Kpi Segment 专题内容Design Privacy Communication Mobile Networking 专题内容Settings Campaign Planning Ebook Business Fitness 视频 Keyword...Company Unsubscribe Analysis 专题内容Browser Premium Internet Promotion 专题内容Loyalty App Affordable Innovation Case 专题内容Saving 专题内容Cloud Image Partner Loyalty Networking Email Feedback 视频 专题内容Cost Planning 专题内容Upload Solution Goal Button Sales Behavior Tutorial 专题内容Ranking Client Forecast Ebook Dashboard Automation Calendar 专题内容Business Platform App Form Supplier 专题内容Photo Contact 专题内容Satisfaction Module Technology Social Project Interface 影视 Se...